$35M+ for Kolltan Pharma

Yale University Medical School spinoff Kolltan Pharmaceuticals of New Haven, CT, announced that it has closed a Series A financing round worth over $35 million. Kolltan is developing cancer treatments based on the work of Yale’s Joseph Schlessinger, a cofounder and director of the startup and its chief scientist. The company also named Michael Schmertzler as its CEO.

Author: Rebecca Zacks

Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.